Biomapas enters US market with Alira Health CMC acquisition

The acquisition of Alira Health’s CMC business establishes Biomapas’ North American presence, adding more than 35 specialists and expanding its support for biopharma companies developing complex biologics and advanced therapies

Biomapas has acquired the Chemistry, Manufacturing and Controls (CMC) business of Alira Health, establishing a new US business, Biomapas North America and expanding its outsourced pharmaceutical development capabilities.

The acquisition brings a Boston-based team of more than 35 CMC specialists into the Biomapas group, adding expertise in outsourced clinical manufacturing, quality assurance, CMC regulatory strategy, regulatory filings and project management.

The team supports preclinical- and clinical-stage biopharma companies developing complex modalities, including monoclonal antibodies, ADCs, oligonucleotides, CAR-T and other cell therapies, as well as small molecules and peptides.

According to Biomapas, the acquired team has supported more than 90 clients across the US and Europe in advancing products into clinical development and towards market.

Existing clients will continue working with the same team and contacts following the transaction.


The move adds CMC capabilities to Biomapas’ existing portfolio of regulatory affairs, pharmacovigilance, clinical development, product and digital consulting services.

The company said the expanded offering will enable it to support pharmaceutical and biotech sponsors earlier in development and across more stages of the product lifecycle.


Xavier Duburcq, CEO of Biomapas, said the acquisition provides a foundation for its North American expansion, adding that CMC is a high-value, regulatory-driven discipline that complements the group's existing services.

The acquisition is backed by majority shareholder Carbyne Equity Partners, which has supported Biomapas since October 2024.

Biomapas accelerates acquisition-led expansion

The Alira Health transaction is the latest in a series of acquisitions as Biomapas broadens its international capabilities.

In August 2025, the company acquired Turkish pharmacovigilance provider Delta PV, strengthening its drug safety services and regional coverage.

In February 2026, Xavier Duburcq was appointed CEO, with the company outlining ambitions to develop into a diversified pharma services platform worth more than €200m. 

More recently, last month Biomapas acquired Pinnaxis, an India-based pharmacovigilance technology and consulting specialist.

The deal added more than 100 technical experts and capabilities in safety system implementation, data migration, automation and analytics. 

You may also like